New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 9, 2013
09:02 EDTLGNDLigand Pharmaceuticals receives equity milestone payment from Retrophin
Ligand Pharmaceuticals has received a milestone payment of 620,000 shares of common stock in newly public partner Retrophin. The milestone arose under the previously executed license agreement for the development and commercialization of Retrophin’s lead clinical candidate RE-021, formerly known as DARA and was triggered by the completion of Retrophin’s merger with Desert Gateway and its transition to a publicly traded company. Ligand will record milestone revenue equal to the estimated fair value of the shares received, which will be determined by an independent valuation firm. The shares issued to Ligand represent approximately 7% of Retrophin’s outstanding capital stock and may be subject to certain trading restrictions. Ligand believes that Retrophin expects to begin enrollment in a Phase 2 clinical trial known as “FONT-3” during the first half of 2013.
News For LGND From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2015
08:52 EDTLGNDAmgen results highlight Ligand royalty strength, says Roth Capital
Roth Capital notes Amgen (AMGN) reported Q2 Kyprolis sales of $119M compared to its estimate of $117M. The drug, alongside Promacta, represent the majority of Ligand's current royalty stream, the firm tells investors. It believes the growth of Kyprolis highlights Ligand's "strong core royalty bearing asset lineup." Roth keeps a Buy rating on the stock with a $135 price target.
July 30, 2015
09:01 EDTLGNDLigand enters license, supply agreement with Sanofi
Subscribe for More Information
July 24, 2015
12:44 EDTLGNDAmgen announces FDA approval of expanded Kyprolis indication
Subscribe for More Information
12:27 EDTLGNDFDA approves expanded use of Kyprolis in multiple myeloma patients
The FDA announced that on July 24 the administration approved carfilzomib, or Kyprolis, marketed by Onyx Pharmaceuticals, an Amgen (AMGN) subsidiary, in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy. The revised labeling includes new Warnings and Precautions for VTE, cardiac toxicities, acute renal failure, pulmonary toxicities, and hypertension. The increased safety risks, including mortality, for elderly patients is described. Detailed safety information in the prescribing information was also updated for use of carfilzomib monotherapy. Reference Link
09:02 EDTLGNDLigand says Revolade recommended by CHMP for EU approval for SAA
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use